TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia

Cell Death and Disease

Volumn 7, Issue 1, 2016, Pages

  Bresin, A ^a   D'Abundo, L ^b   Narducci, M G ^a   Fiorenza, M T ^c   Croce, C M ^d   Negrini, M ^b   Russo, G ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; HEMATOPOIETIC CELL KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE LYN; PROTEIN KINASE SYK; ONCOPROTEIN; TCL1A PROTEIN, HUMAN;

B CELL LEUKEMIA; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; ENDOPLASMIC RETICULUM STRESS; ENZYME PHOSPHORYLATION; EPIGENETICS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL; T CELL LEUKEMIA; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MOUSE; PATHOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS; TUMOR MICROENVIRONMENT;

EID: 84965081503     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.419     Document Type: Review

References (96)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
2. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
3. Binet JL, Lepoprier M, Dighiero G, Charron D, D'Athis P, Vaugier G et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977; 40: 855-864.
4. Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia 2007; 21: 1885-1891.
5. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008; 105: 5166-5171.
6. te Raa GD, Moerland PD, Leeksma AC, Derks IA, Yigittop H, Laddach N et al. Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification. Cell Death Dis 2015; 6: e1852.
7. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
8. Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003; 10: 477-484.
9. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009; 114: 3367-3375.
10. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011; 118: 4313-4320.
11. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006; 66: 11590-11593.
12. Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG et al. Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leuk Res 2007; 31: 1737-1740.
13. Simonetti G, Bertilaccio MT, Ghia P, Klein U. Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy. Blood 2014; 124: 1010-1019.
14. Virgilio L, Narducci MG, Isobe M, Billips LG, Cooper MD, Croce CM et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA 1994; 91: 12530-12534.
15. Narducci MG, Fiorenza MT, Kang SM, Bevilacqua A, Di Giacomo M, Remotti D et al. TCL1 participates in early embryonic development and is over expressed in human seminomas. Proc Natl Acad Sci USA 2002; 99: 11712-11717.
16. Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 2003; 101: 5007-5009.
17. Narducci MG, Pescarmona E, Lazzeri C, Signoretti S, Lavinia AM, Remotti D et al. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res 2000; 60: 2095-2100.
18. Pekarsky Y, Koval A, Hallas C, Bichi R, Tresini M, Malstrom S et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci USA 2000; 97: 3028-3033.
19. Widhopf GF 2nd, Cui B, Ghia EM, Chen L, Messer K, Shen Z et al. ROR1 can interact with TCL1 and enhance leukemogenesis in Emu-TCL1 transgenic mice. Proc Natl Acad Sci USA 2014; 111: 793-798.
20. Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U et al. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci USA 2008; 105: 19643-19648.
21. Gaudio E, Spizzo R, Paduano F, Luo Z, Efanov A, Palamarchuk A et al. Tcl1 interacts with Atm and enhances NF-kappaB activation in hematologic malignancies. Blood 2012; 119: 180-187.
22. Kriss CL, Pinilla-Ibarz JA, Mailloux AW, Powers JJ, Tang CH, Kang CW et al. Over expression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood 2012; 120: 1027-1038.
23. Chen SS, Raval A, Johnson AJ, Hertlein E, Liu TH, Jin VX et al. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2009; 106: 13433-13438.
24. Palamarchuk A, Yan PS, Zanesi N, Wang L, Rodrigues B, Murphy M et al. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci USA 2012; 109: 2555-2560.
25. Fiorenza MT, Torcia S, Canterini S, Bevilacqua A, Narducci MG, Ragone G et al. TCL1 promotes blastomere proliferation through nuclear transfer, but not direct phosphorylation, of AKT/PKB in early mouse embryos. Cell Death Differ 2008; 15: 420-422.
26. Matoba R, Niwa H, Masui S, Ohtsuka S, Carter MG, Sharov AA et al. Dissecting Oct3/4- regulated gene networks in embryonic stemcells by expression profiling. PLoS One 2006; 1: e26.
27. Ragone G, Bresin A, Piermarini F, Lazzeri C, Picchio MC, Remotti D et al. The Tcl1 oncogene defines secondary hair germ cells differentiation at catagen-telogen transition and affects stem-cell marker CD34 expression. Oncogene 2009; 28: 1329-1338.
28. Kang SM, Narducci MG, Lazzeri C, Mongiovi AM, Caprini E, Bresin A et al. Impaired T- and B-cell development in Tcl1-deficient mice. Blood 2005; 105: 1288-1294.
29. Miyazaki T, Miyazaki S, Ashida M, Tanaka T, Tashiro F, Miyazaki J. Functional analysis of Tcl1 using Tcl1-deficient mouse embryonic stem cells. PLoS One 2013; 8: e71645.
30. Virgilio L, Lazzeri C, Bichi R, Nibu K, Narducci MG, Russo G et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci USA 1998; 95: 3885-3889.
31. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002; 99: 6955-6960.
32. Efanov A, Zanesi N, Nazaryan N, Santanam U, Palamarchuk A, Croce CM et al. CD5+CD23 + leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation. Leukemia 2010; 24: 970-975.
33. Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2006; 103: 11713-11718.
34. Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 2006; 108: 1334-1338.
35. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000; 6: 395-407.
36. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008; 111: 846-855.
37. Liu TM, Ling Y, Woyach JA, Beckwith K, Yeh YY, Hertlein E et al. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood 2015; 125: 284-295.
38. Zanesi N, Aqeilan R, Drusco A, Kaou M, Sevignani C, Costinean S et al. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice. Cancer Res 2006; 66: 915-920.
39. Blunt MD, Carter MJ, Larrayoz M, Smith LD, Aguilar-Hernandez M, Cox KL et al. The PI3K/ mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Emicro-TCL1 mouse model. Blood 2015; 125: 4032-4041.
40. Yaktapour N, Ubelhart R, Schuler J, Aumann K, Dierks C, Burger M et al. Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia. Blood 2013; 122: 1621-1633.
41. Holler C, Pinon JD, Denk U, Heyder C, Hofbauer S, Greil R et al. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood 2009; 113: 2791-2794.
42. Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH 3rd et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 2010; 116: 45-53.
43. Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res 2014; 74: 2520-2532.
44. Chen SS, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS et al. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood 2011; 117: 862-871.
45. Chen SS, Sherman MH, Hertlein E, Johnson AJ, Teitell MA, Byrd JC et al. Epigenetic alterations in a murine model for chronic lymphocytic leukemia. Cell Cycle 2009; 8: 3663-3667.
46. Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 2004; 11(Suppl 2): S193-S206.
47. Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 2010; 5: e10941.
48. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-15529.
49. Pekarsky Y, Croce CM. Role of miR-15/16 in CLL. Cell Death Differ 2015; 22: 6-11.
50. Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 2010; 17: 215-220.
51. Liu J, Chen G, Feng L, Zhang W, Pelicano H, Wang F et al. Loss of p53 and altered miR15-a/ 16-1short right arrowMCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/ -) mouse model and primary human leukemia cells. Leukemia 2014; 28: 118-128.
52. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-1801.
53. Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD et al. Karyotypespecific microRNA signature in chronic lymphocytic leukemia. Blood 2009; 114: 3872-3879.
54. Negrini M, Cutrona G, Bassi C, Fabris S, Zagatti B, Colombo M et al. MicroRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters. Clin Cancer Res 2014; 20: 4141-4153.
55. Nana-Sinkam SP, Croce CM. MicroRNA in chronic lymphocytic leukemia: transitioning from laboratory-based investigation to clinical application. Cancer Genet Cytogenet 2010; 203: 127-133.
56. Ouyang YB, Lu Y, Yue S, Giffard RG. miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes. Mitochondrion 2012; 12: 213-219.
57. Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M et al. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 2011; 118: 3072-3079.
58. Bresin A, Callegari E, D'Abundo L, Cattani C, Bassi C, Zagatti B et al. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Emicro-TCL1 mouse model. Oncotarget 2015; 6: 19807-19818.
59. Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J et al. MCL-1 and BCLxL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis 2015; 6: e1593.
60. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013; 34: 592-601.
61. Bernal A, Pastore RD, Asgary Z, Keller SA, Cesarman E, Liou HC et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 2001; 98: 3050-3057.
62. Barragan M, Bellosillo B, Campas C, Colomer D, Pons G, Gil J. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood 2002; 99: 2969-2976.
63. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-13949.
64. Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 2009; 114: 4675-4686.
65. Nganga VK, Palmer VL, Naushad H, Kassmeier MD, Anderson DK, Perry GA et al. Accelerated progression of chronic lymphocytic leukemia in Emu-TCL1 mice expressing catalytically inactive RAG1. Blood 2013; 121: 3855-3866, S3851-S3816.
66. Motiwala T, Zanesi N, Datta J, Roy S, Kutay H, Checovich AM et al. AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia. Blood 2011; 118: 6132-6140.
67. Motiwala T, Kutay H, Zanesi N, Frissora FW, Mo X, Muthusamy N et al. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model. Leukemia 2015; 29: 1350-1359.
68. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen SL et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102: 1515-1525.
69. Chen SS, Batliwalla F, Holodick NE, Yan XJ, Yancopoulos S, Croce CM et al. Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling. Proc Natl Acad Sci USA 2013; 110: E1500-E1507.
70. Duhren-von Minden M, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012; 489: 309-312.
71. Iacovelli S, Hug E, Bennardo S, Duehren-von Minden M, Gobessi S, Rinaldi A et al. Two types of BCR interactions are positively selected during leukemia development in the Emu-TCL1 transgenic mouse model of CLL. Blood 2015; 125: 1578-1588.
72. Suljagic M, Longo PG, Bennardo S, Perlas E, Leone G, Laurenti L et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010; 116: 4894-4905.
73. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213-223.
74. Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood 2014; 123: 1207-1213.
75. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42.
76. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182-1189.
77. Scielzo C, Ghia P, Conti A, Bachi A, Guida G, Geuna M et al. HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. J Clin Invest 2005; 115: 1644-1650.
78. Scielzo C, Bertilaccio MT, Simonetti G, Dagklis A, ten Hacken E, Fazi C et al. HS1 has a central role in the trafficking and homing of leukemic B cells. Blood 2010; 116: 3537-3546.
79. ten Hacken E, Scielzo C, Bertilaccio MT, Scarfo L, Apollonio B, Barbaglio F et al. Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia. Blood 2013; 121: 2264-2273.
80. Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011; 17: 2977-2986.
81. Mittal AK, Chaturvedi NK, Rai KJ, Gilling-Cutucache CE, Nordgren TM, Moragues M et al. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease. Mol Med 2014; 20: 290-301.
82. Heinig K, Gatjen M, Grau M, Stache V, Anagnostopoulos I, Gerlach K et al. Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation. Cancer Discov 2014; 4: 1448-1465.
83. Enzler T, Kater AP, Zhang W, Widhopf GF 2nd, Chuang HY, Lee J et al. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 2009; 114: 4469-4476.
84. Lascano V, Guadagnoli M, Schot JG, Luijks DM, Guikema JE, Cameron K et al. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model. Blood 2013; 122: 3960-3963.
85. Reinart N, Nguyen PH, Boucas J, Rosen N, Kvasnicka HM, Heukamp L et al. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. Blood 2013; 121: 812-821.
86. Fedorchenko O, Stiefelhagen M, Peer-Zada AA, Barthel R, Mayer P, Eckei L et al. CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia. Blood 2013; 121: 4126-4136.
87. Di Lillo DJ, Weinberg JB, Yoshizaki A, Horikawa M, Bryant JM, Iwata Y et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia 2013; 27: 170-182.
88. Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R, Liu F et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA 2009; 106: 6250-6255.
89. Hofbauer JP, Heyder C, Denk U, Kocher T, Holler C, Trapin D et al. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia 2011; 25: 1452-1458.
90. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118: 2427-2437.
91. McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D et al. Mechanisms of PD-L1/PD-1 mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Emu-TCL1 CLL mouse model. Blood 2015; 126: 212-221.
92. Gassner FJ, Zaborsky N, Catakovic K, Rebhandl S, Huemer M, Egle A et al. Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model. Br J Haematol 2015; 170: 515-522.
93. McClanahan F, Hanna B, Miller S, Clear AJ, Lichter P, Gribben JG et al. PD-L1 Checkpoint Blockade Prevents Immune Dysfunction and Leukemia Development in a Mouse Model of Chronic Lymphocytic Leukemia. Blood 2015; 126: 203-211.
94. Wu QL, Buhtoiarov IN, Sondel PM, Rakhmilevich AL, Ranheim EA. Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia. J Immunol 2009; 182: 6771-6778.
95. Bertilaccio MT, Simonetti G, Dagklis A, Rocchi M, Rodriguez TV, Apollonio B et al. Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models. Blood 2011; 118: 660-669.
96. Asslaber D, Pinon JD, Seyfried I, Desch P, Stocher M, Tinhofer I et al. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood 2010; 115: 4191-4197.